Combination therapy with S-1, oxaliplatin and leucovorin in patients with advanced esophageal squamous cell carcinoma

Naohiro Nishida, Makoto Yamsaki, Kazuki Odagiri, Kotaro Yamashita, Koji Tanaka, Daisuke Sakai, Tomoki Makino, Tsuyoshi Takahashi, Yukinori Kurokawa, Taroh Satoh, Masaki Mori, Yuichiro Doki

研究成果: Contribution to journalArticle査読

1 被引用数 (Scopus)

抄録

Background/Aim: In this study, we assessed the safety and efficacy of combination therapy with S-1, oxaliplatin and leucovorin (SOL) in advanced esophageal squamous cell carcinoma (ESCC) patients. Patients and Methods: Ten unresectable or recurrence ESCC patients, who had been previously treated with more than two regimens were included in this study. The treatment schedule comprised S-1 40-60 mg and fixed dose of leucovorin 25 mg together orally twice a day for one week, followed by one-week of rest. Oxaliplatin 85 mg/m2 was given as an intravenous infusion on day one, repeated every two weeks. Results: Of the eight patients with measurable lesions, two patients with partial response (25%) and two with stable disease (25%) were observed. Disease control rate was 50%. Median progression-free survival and overall survival were 5.0 and 9.3 months, respectively. The main common adverse events were malaise (60%), decreased appetite (50%), peripheral sensory neuropathy (40%). Conclusion: SOL therapy showed promising antitumor activity with acceptable toxicity even for heavily pretreated ESCC.

本文言語英語
ページ(範囲)2249-2254
ページ数6
ジャーナルIn Vivo
33
6
DOI
出版ステータス出版済み - 2019

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

フィンガープリント 「Combination therapy with S-1, oxaliplatin and leucovorin in patients with advanced esophageal squamous cell carcinoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル